Icosavax

Icosavax, Inc. engages in the development and commercialization of vaccines against infectious diseases. It focuses on developing vaccine candidates for viral causes of pneumonia in older adults. The company was founded by Neil King and David Baker on November 1, 2017 and is headquartered in Seattle, WA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases.

- Positive topline interim Phase 1 results for bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults -

Icosavax Reports Second Quarter 2023 Financial Results and Provides Corporate Update

- In new data from Icosavax's IVX-121 Phase 1b extension trial in older adults, GMTs against RSV through day 365 persisted at ~45-70% of the GMTs at day 28 (for 75 and 250 µg unadjuvanted dosages) -

Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121 Against RSV and Initial Evidence for Revaccination Potential

Icosavax, a US biotech company, is developing vaccines for respiratory viruses using a proprietary virus-like particle technology; its lead product, RSV+hMPV vaccine, could become a multi-billion dollar franchise. The company's IVX-A12 vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) has shown promising phase 1 results and received FDA's Fast Track designation. Despite risks associated with clinical trials, regulatory approvals, competition, and market acceptance, we initiate Icosavax stock with a speculative buy rating.

Icosavax: Moderna 2.0, The Microscopic Giant In The Vaccine Arena

- Phase 2 topline interim results expected in 1Q 2024 - - 6-month durability data for Phase 1 trial of IVX-A12 also expected in 1Q 2024 - SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced the initiation of a Phase 2 clinical trial of IVX-A12, a combination bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) virus like particle (VLP) vaccine candidate, in older adults. IVX-A12 is a liquid, refrigerator-stable formulation comprised of IVX-121, Icosavax's RSV prefusion F protein VLP vaccine candidate, and IVX-241, Icosavax's hMPV prefusion F protein VLP vaccine candidate.

Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults

Icosavax (ICVX) surges on positive data from the clinical study of IVX-A12, targeting respiratory syncytial virus and human metapneumovirus in older adults.

Icosavax (ICVX) Up on Positive VLP Vaccine Candidate Data

Icosavax also initiated a $67.8 million stock sale. The biopharmaceutical company's pipeline also includes vaccines to treat influenza and severe acute respiratory syndrome coronavirus.

Why Shares of Icosavax Jumped on Tuesday

SEATTLE, May 22, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 8,369,754 shares of its common stock at a purchase price of $8.10 per share. The financing was led by new investor TCGX with participation by additional new investors including Logos Capital and Vivo Capital. All of the shares are to be sold by Icosavax. Icosavax expects to receive gross proceeds of approximately $67.8 million from the offering.

Icosavax Announces $67.8 Million Registered Direct Offering of Common Stock

–  IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV in older adults – –  IVX-A12 was generally well tolerated with no vaccine-related SAEs – –  First demonstration of hMPV vaccine immunogenicity in an older adult population – –  No evidence of immune interference; initial indication of combinability achievable with company's VLP technology – –  Next steps: Icosavax plans to initiate a Phase 2 immunogenicity trial for IVX-A12 in mid-2023, to be followed by an hMPV human challenge study as proof-of-concept efficacy study – –  Concurrent $67.8 million registered direct offering; extends cash runway into 2H 2025 – –  Company to host conference call/webcast today at 6:00 p.m. ET / 3:00 p.m.

Icosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults

Icosavax (ICVX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Icosavax (ICVX) Ahead of Earnings?

Icosavax, Inc. (ICVX) came out with a quarterly loss of $0.60 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.60 per share a year ago.

Icosavax, Inc. (ICVX) Reports Q1 Loss, Lags Revenue Estimates

- IVX-A12 (RSV+hMPV) Phase 1 topline interim data expected in 2Q 2023 - - Initiation of IVX-A12 Phase 2 trial expected in 2H 2023 - - Cash and cash equivalents, restricted cash, and short-term investments of $197.7M at end 1Q 2023 - SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. “We started 2023 with positive momentum with receipt of Fast Track designation for our bivalent RSV/hMPV vaccine candidate, IVX-A12, and completion of dosing in its Phase 1 clinical trial.

Icosavax Reports First Quarter 2023 Financial Results and Provides Corporate Update

Icosavax, Inc. (ICVX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Icosavax, Inc. (ICVX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Nkarta, Inc.

Biotech stock fortunes hinge upon potential, progress, and the ultimate realization of drugs and devices that treat diseases. Stringent regulatory processes and long development times result in substantial costs.

3 Biotech Stocks to Watch for Potential Breakthroughs

- FDA granted Fast Track Designation for IVX-A12, a bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine candidate -

Icosavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

SEATTLE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one meetings at the following investor conferences:

Icosavax to Participate in the Upcoming Healthcare Conferences

SEATTLE, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IVX-A12, a bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine candidate, in older adults 60 years of age and above.

Icosavax Granted FDA Fast Track Designation for IVX-A12

- Recently reported positive six-month immunogenicity data for IVX-121 against RSV; first clinical evidence of potential differentiation on durability with company's VLP platform -

Icosavax Provides Corporate Update and Anticipated Milestones for 2023

Data from an early-stage study showed that Icosavax's (ICVX) investigational RSV vaccine exhibited sustained immunologic response following six months of dose administration.

Icosavax (ICVX) Up 112% on Upbeat Data From RSV Jab Study

- In new data from Phase 1/1b study, IVX-121 showed sustained immunologic response at six months; geometric mean titers (GMT) against RSV-A through day 180 persisting at 64-98% of the GMTs at day 28 in older adults -

Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint

SEATTLE, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one meetings at the 5th Annual Evercore ISI HealthCONx Conference taking place November 29 through December 1, 2022.

Icosavax to Participate in the Evercore ISI HealthCONx Conference

Icosavax, Inc. (ICVX) delivered earnings and revenue surprises of 3.51% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Icosavax, Inc. (ICVX) Reports Q3 Loss, Lags Revenue Estimates

- Initiated a Phase 1 trial of Icosavax's first combination bivalent vaccine candidate, IVX-A12, against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults -

Icosavax Reports Third Quarter Financial Results and Provides Corporate Update

SEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one meetings at the following investor conferences:

Icosavax to Participate in in Upcoming Investor Conferences

- IVX-A12 is the first combination bivalent vaccine candidate against both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) to reach clinical stage -

Icosavax Initiates Phase 1 Trial of IVX-A12 Against RSV and hMPV in Older Adults

Icosavax, Inc. (ICVX) delivered earnings and revenue surprises of -3.64% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Icosavax Stock (ICVX)